Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma

Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma

Bibliographic Details
Main Author:	McGettigan, Suzanne
Format:	Online
Language:	English
Published:	Harborside Press 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114496/

Similar Items

Dabrafenib for treatment of BRAF-mutant melanoma
by: Kainthla, Radhika, et al.
Published: (2013)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
by: Banzi, Maria, et al.
Published: (2016)

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report
by: Casadevall, David, et al.
Published: (2016)

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
by: Luke, Jason J, et al.
Published: (2014)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
by: Homet Moreno, Blanca, et al.
Published: (2015)

Dabrafenib and its potential for the treatment of metastatic melanoma
by: Menzies, Alexander M, et al.
Published: (2012)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
by: Ponti, Giovanni, et al.
Published: (2012)

Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
by: Cocorocchio, E, et al.
Published: (2016)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
by: Spagnolo, Francesco, et al.
Published: (2014)

Clinical significance of BRAF mutations in metastatic melanoma
by: Chang, David Z, et al.
Published: (2004)

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
by: Valpione, Sara, et al.
Published: (2015)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
by: Borch, Troels Holz, et al.
Published: (2014)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma12
by: Kim, Hee Kyung, et al.
Published: (2016)

A Case of Intracranial Hemorrhage Caused by Combined Dabrafenib and Trametinib Therapy for Metastatic Melanoma
by: Lee, Le Min, et al.
Published: (2014)

Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature
by: Garrett, Giorgia L., et al.
Published: (2015)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
by: Smalley, Keiran SM, et al.
Published: (2015)

Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
by: Garrisi, Vito Michele, et al.
Published: (2014)

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
by: Curl, Patti, et al.
Published: (2014)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
by: Shelledy, Lindsay, et al.
Published: (2015)

Correction: Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
Published: (2015)

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
by: Curl, Patti, et al.
Published: (2015)

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
by: Satzger, Imke, et al.
Published: (2015)

Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
by: Puzanov, Igor
Published: (2015)

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy
by: Williams, Casey B, et al.
Published: (2015)

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance
by: Falchook, G.S., et al.
Published: (2013)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek Tanja, et al.
Published: (2016-09-01)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek, Tanja, et al.
Published: (2016)

The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
by: Porcelli, Letizia, et al.
Published: (2015)

Endoplasmic reticulum stress-induced autophagy determines the susceptibility of melanoma cells to dabrafenib
by: Ji, Chao, et al.
Published: (2016)

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
by: Draganova, Dafina, et al.
Published: (2015)

Novel combination therapies for BRAF-mutant melanoma
by: McArthur, Grant A
Published: (2015)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
by: Goldinger, Simone M., et al.
Published: (2013)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
by: Fisher, Rosalie, et al.
Published: (2012)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
by: Sigalotti, L, et al.
Published: (2011)

The role of BRAF V600 mutation in melanoma
by: Ascierto, Paolo A, et al.
Published: (2012)

Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas
by: Lee, Hyoun Wook, et al.
Published: (2012)

Acute visual loss after ipilimumab treatment for metastatic melanoma
by: Wilson, Melissa A., et al.
Published: (2016)

BRAF-targeted therapy and immune responses to melanoma
by: Ngiow, Shin Foong, et al.
Published: (2013)

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
by: King, Alastair J., et al.
Published: (2013)

Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations
by: Gentilcore, Giusy, et al.
Published: (2013)